Total Payments
$212,409
2024 Payments
$1,723
Companies
29
Transactions
486
Medicare Patients
3,325
Medicare Billing
$452,672
Payment Breakdown by Category
Research$201,099 (94.7%)
Food & Beverage$10,152 (4.8%)
Travel$1,045 (0.5%)
Education$113.68 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $201,099 | 46 | 94.7% |
| Food and Beverage | $10,152 | 434 | 4.8% |
| Travel and Lodging | $1,045 | 3 | 0.5% |
| Education | $113.68 | 3 | 0.1% |
Payments by Type
Research
$201,099
46 transactions
General
$11,311
440 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $121,185 | 4 | $0 (2021) |
| Lupin Inc. | $77,309 | 20 | $0 (2018) |
| GlaxoSmithKline, LLC. | $4,598 | 126 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,110 | 100 | $0 (2024) |
| Allergan Inc. | $1,477 | 7 | $0 (2019) |
| GENZYME CORPORATION | $848.62 | 37 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $711.97 | 37 | $0 (2024) |
| Grifols USA, LLC | $603.61 | 36 | $0 (2024) |
| Insmed, Inc. | $437.24 | 22 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $413.21 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,723 | 81 | GlaxoSmithKline, LLC. ($472.47) |
| 2023 | $1,905 | 75 | AstraZeneca Pharmaceuticals LP ($731.16) |
| 2022 | $1,494 | 66 | AstraZeneca Pharmaceuticals LP ($395.20) |
| 2021 | $122,151 | 56 | Eli Lilly and Company ($121,185) |
| 2020 | $2,705 | 78 | GlaxoSmithKline, LLC. ($1,709) |
| 2019 | $2,657 | 65 | Allergan Inc. ($1,477) |
| 2018 | $77,933 | 41 | Lupin Inc. ($77,309) |
| 2017 | $1,841 | 24 | GlaxoSmithKline, LLC. ($1,322) |
All Payment Transactions
486 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.91 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: Pulmonology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: Respiratory | ||||||
| 11/24/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: RESPIRATORY | ||||||
| 11/20/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Pulmonology | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: Respiratory | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: RESPIRATORY | ||||||
| 10/22/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $8.55 | General |
| Category: Immunology | ||||||
| 10/17/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Pulmonology | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Respiratory | ||||||
| 10/16/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.90 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/11/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Respiratory | ||||||
| 10/08/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $10.88 | General |
| Category: RESPIRATORY | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $28.08 | General |
| Category: Respiratory | ||||||
| 09/18/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Pulmonology | ||||||
| 09/16/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: RESPIRATORY | ||||||
| 09/10/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: IMMUNOLOGY | ||||||
| 08/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $105,644 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $77,309 | 20 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $15,541 | 2 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | GlaxoSmithKline, LLC. | $1,350 | 13 |
| A 24 month double blind randomised parallel group study to determine the effect of Anoro on symptoms vs Tiotropium | GlaxoSmithKline, LLC. | $1,255 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 895 | 1,768 | $289,984 | $115,745 |
| 2022 | 19 | 894 | 1,840 | $261,132 | $105,556 |
| 2021 | 15 | 772 | 1,262 | $305,853 | $116,277 |
| 2020 | 18 | 764 | 1,373 | $319,434 | $115,093 |
Total Patients
3,325
Total Services
6,243
Medicare Billing
$452,672
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 647 | $119,048 | $58,212 | 48.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 134 | $28,676 | $11,839 | 41.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 30 | 75 | $39,225 | $11,452 | 29.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 59 | 59 | $16,697 | $6,780 | 40.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 48 | $19,536 | $6,300 | 32.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 98 | $12,250 | $6,167 | 50.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 46 | 93 | $13,857 | $5,515 | 39.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 64 | 65 | $6,575 | $2,470 | 37.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 69 | 72 | $12,600 | $1,779 | 14.1% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 59 | 60 | $6,000 | $1,768 | 29.5% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 72 | 76 | $7,667 | $1,406 | 18.3% |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Office | 2023 | 20 | 27 | $1,512 | $704.26 | 46.6% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 23 | 39 | $1,170 | $542.10 | 46.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 36 | $2,340 | $369.79 | 15.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 11 | 11 | $1,463 | $248.02 | 17.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 16 | 228 | $1,368 | $192.16 | 14.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 214 | 528 | $97,152 | $47,445 | 48.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 31 | 83 | $43,409 | $13,256 | 30.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 49 | 136 | $29,104 | $10,227 | 35.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 70 | 70 | $19,810 | $8,229 | 41.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 42 | 45 | $18,315 | $6,526 | 35.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 69 | 102 | $7,548 | $4,274 | 56.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 63 | $7,875 | $4,041 | 51.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 33 | 52 | $7,748 | $2,774 | 35.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 50 | 50 | $4,700 | $2,010 | 42.8% |
About Dr. Nancy Patel, DO
Dr. Nancy Patel, DO is a Internal Medicine healthcare provider based in Clinton, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912119371.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nancy Patel, DO has received a total of $212,409 in payments from pharmaceutical and medical device companies, with $1,723 received in 2024. These payments were reported across 486 transactions from 29 companies. The most common payment nature is "" ($201,099).
As a Medicare-enrolled provider, Patel has provided services to 3,325 Medicare beneficiaries, totaling 6,243 services with total Medicare billing of $452,672. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Clinton, SC
- Active Since 05/05/2007
- Last Updated 11/02/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1912119371
Products in Payments
- TIOTROPIUM (Drug) $77,309
- NUCALA (Biological) $1,963
- ANORO (Drug) $1,373
- DUPIXENT (Biological) $1,272
- TRELEGY ELLIPTA (Drug) $1,133
- FASENRA (Biological) $909.98
- FASENRA (Drug) $646.70
- Prolastin-C Liquid (Biological) $567.05
- TEZSPIRE (Biological) $509.94
- Arikayce (Drug) $421.00
- GLASSIA (Biological) $388.18
- OFEV (Drug) $367.12
- BEVESPI AEROSPHERE (Drug) $326.19
- BREZTRI (Drug) $323.65
- SYMBICORT (Drug) $210.95
- STIOLTO RESPIMAT (Drug) $183.80
- AIRSUPRA (Drug) $182.87
- (8876) Vest Therapy Und (Device) $136.67
- ORENITRAM (Drug) $135.53
- LONHALA MAGNAIR (Drug) $120.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Clinton
Farrukh Kureishy, Md, MD
Internal Medicine — Payments: $145,766
Internal Medicine $145,766
Dr. Param Singh, Md, MD
Internal Medicine — Payments: $49,005
Internal Medicine $49,005
Dr. Anita Vaughn, Md, MD
Internal Medicine — Payments: $34,450
Internal Medicine $34,450
Patrick Boler, M.d, M.D
Internal Medicine — Payments: $16,457
Internal Medicine $16,457
Dr. Victor Herry
Internal Medicine — Payments: $14,628
Internal Medicine $14,628
Dr. Paul Manning, M.d, M.D
Internal Medicine — Payments: $8,944
Internal Medicine $8,944